Ubiquitin and cancer: from molecular targets and mechanisms to the clinic -- AACR Special Conference.
Colland
Frederic
F
Hybrigenics SA, 3-5 impasse Reille, 75014 Paris, France. fcolland@hybrigenics.com
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D001897:Boronic Acids / Q000494:pharmacology / Q000627:therapeutic use; D000069286:Bortezomib; D049109:Cell Proliferation / Q000187:drug effects; D002986:Clinical Trials as Topic; D000074749:Deubiquitinating Enzyme CYLD; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000378:metabolism; D011480:Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D061988:Proteasome Inhibitors; D011719:Pyrazines / Q000494:pharmacology / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects; D025521:Tumor Suppressor Proteins / Q000378:metabolism; D025801:Ubiquitin / Q000378:metabolism*; D044767:Ubiquitin-Protein Ligases / Q000378:metabolism; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011480:Protease Inhibitors; D061988:Proteasome Inhibitors; D011719:Pyrazines; D025521:Tumor Suppressor Proteins; D025801:Ubiquitin; D000069286:Bortezomib; D044767:Ubiquitin-Protein Ligases; C409984:CYLD protein, human; D000074749:Deubiquitinating Enzyme CYLD; D046988:Proteasome Endopeptidase Complex